NCT04474938 Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis Status UNKNOWN Phase PHASE2
NCT04407442 Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab Status TERMINATED Phase PHASE2
NCT04352205 Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure Status TERMINATED Phase PHASE2
NCT04304144 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis Status COMPLETED Phase PHASE2
NCT04280328 Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT04268498 A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04264884 Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab Status APPROVED_FOR_MARKETING Phase N/A
NCT04251065 Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH Status TERMINATED Phase PHASE2
NCT04246047 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04230304 Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Status TERMINATED Phase PHASE2
NCT04230031 Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma Status WITHDRAWN Phase PHASE2
NCT04223661 Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy Status WITHDRAWN Phase PHASE2
NCT04205240 Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Status TERMINATED Phase PHASE2
NCT04181827 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04176718 Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Status RECRUITING Phase PHASE2
NCT04166565 Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04140162 Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04139304 A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma Status RECRUITING Phase EARLY_PHASE1
NCT04136756 NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1
NCT04133636 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2